Minerva Neurosciences director William Doyle resigns; board appoints replacements

Minerva Neurosciences, Inc.

William Doyle resigned from the Board effective May 3, 2023, including as Chair of Compensation Committee.
Mr. Doyle's resignation was not due to any disagreement with the Company, management, or Board.
Fouzia Laghrissi-Thode, M.D., appointed Chair of Compensation Committee effective May 3, 2023.
Hans Peter Hasler appointed as a new member of Audit Committee effective May 3, 2023.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

William Doyle

Director

NERV · Minerva Neurosciences, Inc.

Effective: 2023-05-03
Filed: May 5, 2023, 7:59 PM ET

On May 3, 2023, William Doyle notified the Board of Directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) of his intention to resign as a member of the Board, effective May 3, 2023, including from his role as Chair of the Compensation Committee of the Board and a member of the Audit Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William Doyle resigned as Director at Minerva Neurosciences, Inc..

Action: resigned
Role: Director

Exact text from the filing

On May 3, 2023, William Doyle notified the Board of Directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) of his intention to resign as a member of the Board, effective May 3, 2023, including from his role as Chair of the Compensation Committee of the Board and a member of the Audit Committee of the Board.

View on SEC.gov

Minerva Neurosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-137134

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.